ArticleFrontiers in oncology2025

Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction.

Baoxuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.